COVID-19's Impact on the Pharma Trade & Supply Chain, Q3 2020 Findings
Dublin, Nov. 18, 2020 (GLOBE NEWSWIRE) -- The "Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) Impact" report has been added to ResearchAndMarkets.com's offering.
This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing.
Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe.
Report Scope
The report provides in-house analyst expertise on the results of a 5-minute survey of 75 of the publisher's Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020.
Reasons to Buy
Benchmark companies' primary concerns
Determine the impact of COVID-19 to date on supply chains
Assess companies' strategic future plans
Track changes to corporate strategy and attitudes
Key Topics Covered
Executive Summary
Study Design
Background, Objectives, and Design
Respondent Mix
Primary Business Concerns
Impact of COVID-19 on Company Revenue
Dedicated Planning Team
Supply Chain Concerns
Clinical Trial Materials
Marketed Drugs
Spotlight on US Manufacturing
Import/Export Risks
Clinical Trial Concerns
Addressing Clinical Trial Disruptions
Planning Scenarios
In Their Own Words
Suppliers
Manufacturing Sites
Small Molecule API
Summary
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/9jrtom
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900